

OMTM, Volume 9

Supplemental Information

Immunomonitoring of MSC-Treated GvHD Patients

Reveals Only Moderate Potential for Response

Prediction but Indicates Treatment Safety

Joni Keto, Tanja Kaartinen, Urpu Salmenniemi, Johanna Castrén, Jukka Partanen, Arno Hänninen, Matti Korhonen, Kaarina Lähteenmäki, Maija Itälä-Remes, and Johanna Nystedt




Figure S1. T helper cell population kinetics during MSC therapy.

Relative proportions of T helper cells (Th1, blue; Th2, orange; Th17, green; Treg, violet) were measured as described in the Materials and methods, and are shown individually for each patient. The sampling time points are shown in the x-axes; samples were collected before (0d) and approximately one week (7d) and one month (28d) after the first MSC dose. Details of the sampling time points are indicated in Table 1. The y-axes show the proportions of Th cell populations in percentage. Measurements with results below the detection limit (0.2 %) are not shown.